Folgen
Erwan Bezard
Erwan Bezard
Bestätigte E-Mail-Adresse bei u-bordeaux.fr - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
MC Rodriguez-Oroz, M Jahanshahi, P Krack, I Litvan, R Macias, E Bezard, ...
The Lancet Neurology 8 (12), 1128-1139, 2009
11022009
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
JA Obeso, M Stamelou, CG Goetz, W Poewe, AE Lang, D Weintraub, ...
Movement disorders 32 (9), 1264-1310, 2017
8792017
Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys
A Recasens, B Dehay, J Bové, I Carballo‐Carbajal, S Dovero, ...
Annals of neurology 75 (3), 351-362, 2014
6972014
A brain–spine interface alleviating gait deficits after spinal cord injury in primates
M Capogrosso, T Milekovic, D Borton, F Wagner, EM Moraud, ...
Nature 539 (7628), 284-288, 2016
6772016
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
E Bezard, JM Brotchie, CE Gross
Nature Reviews Neuroscience 2 (8), 577-588, 2001
6542001
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque …
E Bezard, S Dovero, C Prunier, P Ravenscroft, S Chalon, D Guilloteau, ...
Journal of Neuroscience 21 (17), 6853-6861, 2001
5952001
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
B Dehay, M Bourdenx, P Gorry, S Przedborski, M Vila, S Hunot, ...
The Lancet Neurology 14 (8), 855-866, 2015
5372015
Priorities in Parkinson's disease research
WG Meissner, M Frasier, T Gasser, CG Goetz, A Lozano, P Piccini, ...
Nature reviews Drug discovery 10 (5), 377-393, 2011
5262011
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
MF Bastide, WG Meissner, B Picconi, S Fasano, PO Fernagut, M Feyder, ...
Progress in neurobiology 132, 96-168, 2015
5012015
Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia
I Aubert, C Guigoni, K Håkansson, Q Li, S Dovero, N Barthe, BH Bioulac, ...
Annals of Neurology: Official Journal of the American Neurological …, 2005
4592005
Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives
AHV Schapira, CW Olanow, JT Greenamyre, E Bezard
The Lancet 384 (9942), 545-555, 2014
4562014
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
E Bézard, S Ferry, U Mach, H Stark, L Leriche, T Boraud, C Gross, ...
Nature medicine 9 (6), 762-767, 2003
4522003
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
B Boland, WH Yu, O Corti, B Mollereau, A Henriques, E Bezard, ...
Nature reviews Drug discovery 17 (9), 660-688, 2018
4452018
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders
V Voon, PO Fernagut, J Wickens, C Baunez, M Rodriguez, N Pavon, ...
The Lancet Neurology 8 (12), 1140-1149, 2009
4342009
The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders
P Sokoloff, J Diaz, BL Foll, O Guillin, L Leriche, E Bezard, C Gross
CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2006
4172006
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
E Bezard, CE Gross, JM Brotchie
Trends in neurosciences 26 (4), 215-221, 2003
4142003
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration
B Dehay, A Ramirez, M Martinez-Vicente, C Perier, MH Canron, ...
Proceedings of the National Academy of Sciences 109 (24), 9611-9616, 2012
3822012
Novel pharmacological targets for the treatment of Parkinson's disease
AHV Schapira, E Bezard, J Brotchie, F Calon, GL Collingridge, B Ferger, ...
Nature reviews Drug discovery 5 (10), 845-854, 2006
3802006
Spatiotemporal neuromodulation therapies engaging muscle synergies improve motor control after spinal cord injury
N Wenger, EM Moraud, J Gandar, P Musienko, M Capogrosso, L Baud, ...
Nature medicine 22 (2), 138-145, 2016
3582016
Lysosomal impairment in Parkinson's disease
B Dehay, M Martinez‐Vicente, GA Caldwell, KA Caldwell, Z Yue, ...
Movement Disorders 28 (6), 725-732, 2013
3542013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20